The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of S-1 in patients (pts) with previously treated Invasive thymoma (IT) and thymic carcinoma (TC): North Japan Lung Cancer Study Group Trial 1203.
 
Kyoji Tsurumi
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Shoichi Kuyama
No Relationships to Disclose
 
Taku Nakagawa
No Relationships to Disclose
 
Daijiro Harada
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Yakult Honsha
 
Yoko Tsukita
No Relationships to Disclose
 
Hisashi Tanaka
No Relationships to Disclose
 
Kana Watanabe
No Relationships to Disclose
 
Yoshiaki Mori
No Relationships to Disclose
 
Toshiyuki Harada
Honoraria - Boehringer Ingelheim; GlaxoSmithKline K.K.; Hisamitsu Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Boehringer Ingelheim
 
Toshihiko Hino
No Relationships to Disclose
 
Masanori Fujii
No Relationships to Disclose
 
Akira Inoue
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mundipharma; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan; MSD
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Shionogi (Inst)